

Molecular Testing for Transplant Recipients

Advances in transplant medicine have produced immunosuppressive and therapeutic agents that have improved the outcomes of transplant recipients diagnosed with viral infections. Even with such improvements, new viral infections or reactivation of endogenous, latent viruses can lead to clinical manifestations that contribute to morbidity and mortality in transplant recipients.¹ Molecular testing for transplant-associated viruses has replaced most serologic and in vitro culture methods for the diagnosis and monitoring of infection. Furthermore, quantitative molecular tests (viral loads) allow the customization of antiviral and immunosuppressive therapies to prevent and treat infection.^{2,3} These molecular tests allow for improvements in viral detection and quantitative monitoring, helping to minimize the clinical impact of viral infections and improve the outcome of patients undergoing organ and tissue transplantation.^{1,2,4}

BK Virus

BK virus (BKV) is a member of the polyomaviruses. BKV is associated with a variety of clinical features in the immunocompromised host: viremia, viruria, ureteral lesions, and cystitis.^{5,6} BKV infections are common, with more than 70% of the general population worldwide presenting with serological evidence of exposure to BKV.⁷ In many individuals, the virus remains latent after initial infection.⁸ BKV-associated nephropathy has emerged as a cause of allograft failure linked to immunosuppressive agents, affecting up to 8% of kidney transplants.⁹ BKV is also common in bone marrow transplant patients with hemorrhagic cystitis.¹⁰ The BKV viral load in plasma and urine has been shown to be higher in patients with BKV nephropathy than in those without nephropathy.⁹ Testing for BKV DNA in plasma from renal-allograft recipients by PCR is a sensitive and specific method for identifying viral nephropathy.¹¹

Quantitative Testing

[BK Virus Quantitation, Real-time DNA PCR \(138962\)](#)

[BK Virus Quantitation, Real-time PCR, Urine \(138880\)](#)

Cytomegalovirus (CMV)

CMV is a common infectious agent among transplant recipients and can manifest in many ways in immunocompromised patients, including pneumonia, colitis, and retinitis.¹² Chronic CMV infections increase the risk of graft rejection in transplant recipients and are also associated with subsequent infections with other microbiological pathogens.³ Monitoring CMV in conjunction with 2 antiviral strategies (preemptive and prophylactic antiviral therapy) can decrease or prevent clinical complications in patients after allogeneic hematopoietic stem cell transplantation (HSCT).¹³⁻¹⁴ Preemptive antiviral therapy has greatly reduced the incidence and mortality rate of CMV disease, especially when Ag- or PCR-based CMV monitoring is performed.¹⁴ The International Herpes Management Forum recommended PCR testing for diagnosis of CMV infection and CMV load measurements for prognosis and for monitoring response to anti-CMV therapy in their 2004 guidelines for diagnosing and monitoring CMV in transplant patients.¹⁵

Qualitative Testing

[Cytomegalovirus \(CMV\) DNA PCR General \(138693\)](#)

Quantitative Testing

[Cytomegalovirus \(CMV\) DNA PCR Plasma \(139149\)](#)

[Cytomegalovirus \(CMV\) DNA PCR Urine \(139144\)](#)

Epstein-Barr Virus (EBV)

Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) is a serious complication following many bone marrow transplants and, in some cases, may be fatal.¹⁶ Posttransplant lymphoproliferative disorders (PTLD) are also associated with solid organ transplant, and a spectrum of clinical features makes diagnosis difficult.¹⁷ PCR testing for EBV may allow for early detection and monitoring and facilitate therapy decisions that minimize the spread of disease.¹⁸ For example, recipients of T-cell depleted transplants are at high risk for developing EBV-LPD with even low virus levels (quantified viral DNA levels of 1000 genome equivalents/mL).^{4,17} Early diagnosis of EBV-PTLD is important, because many patients respond to reduction in immunosuppression, especially if PTLD is detected at an early stage.¹⁸

Qualitative Testing

[Epstein-Barr Virus DNA PCR, Qualitative \(138289\)](#)

Quantitative Testing

[Epstein-Barr Virus, Quantitative, Viral Load \(138230\)](#)

Human Herpesvirus 6 (HHV-6)

Human herpesvirus 6 reactivation is common after allogeneic hematopoietic stem cell transplant (HSCT), because many patients are latently infected with 1 or more viral strains.¹⁹⁻²⁰ HHV-6 is associated with subsequent delayed monocyte and platelet engraftment, increased platelet transfusion requirements, all-cause mortality, grade 3-4 graft-versus-host disease (GVHD), and CNS dysfunction.²⁰ Two HHV-6 subtypes are known, with most primary HHV-6 infections caused by subtype 6B.²¹ Both subtypes can be detected in a highly sensitive and very specific manner with real-time PCR.

Qualitative Testing

[Human Herpesvirus Type 6 \(HHV-6\) DNA PCR \(138479\)](#)

Quantitative Testing

[HHV-6 Quantitation DNA PCR \(139310\)](#)





Other molecular tests for transplant patients include:

- Adenovirus (138164)
- *Chlamydia pneumoniae* (138263)
- Herpes Simplex Virus 1-2 (HSV-1/2) (138651)
- Mycoplasma and Ureaplasma (138778)
- *Mycoplasma pneumoniae* (138420)
- Norovirus (138307)
- Parvovirus (138644)
- Respiratory Virus Panel (139250)
- *Toxoplasma* (138602)
- Varicella-Zoster Virus (VZV) (138313)

For additional information, please refer to the **LabCorp Directory of Services and Interpretive Guide** or contact client services at **800-582-0077**.

References

1. Moss P. Developments in the treatment of post-transplant viral disease. *Best Pract Res Clin Haematol*. Dec 2001; 14(4):777-792.
2. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. *J Am Soc Nephrol*. Jun 2005; 16(6):1758-1774.
3. Jenkins FJ, Rowe DT, Rinaldo CR Jr. Herpesvirus infections in organ transplant recipients. *Clin Diagn Lab Immunol*. 2003 Jan; 10(1):1-7.
4. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. *Blood*. 2002 Jun 15; 99(12):4364-4369.
5. Randhawa P, Ho A, Shapiro R, et al. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. *J Clin Microbiol*. 2004 Mar; 42(3):1176-1180.
6. Kwak EJ, Vilchez RA, Randhawa P, Shapiro R, Butel JS, Kusne S. Pathogenesis and management of polyomavirus infection in transplant recipients. *Clin Infect Dis*. 2002 Nov 1; 35(9):1081-1087.
7. Hirsch HH. BK virus: Opportunity makes a pathogen. *Clin Infect Dis*. 2005 Aug 1; 41(3):354-360.
8. Hurault de Ligny B, Etienne I, François A, et al. Polyomavirus-induced acute tubulo-interstitial nephritis in renal allograft recipients. *Transplantation Proc*. 2000 Dec; 32(8):2760-2761.
9. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *N Engl J Med*. 2002 Aug 15; 347(7):488-496.
10. Leung AYH, Suen CKM, Lie AKW, Liang RHS, Yuen KY, Kwong YL. Quantification of polyoma BK viraemia in hemorrhagic cystitis complicating bone marrow transplantation. *Blood*. 2001 Sep 15; 98(6):1971-1978.
11. Nickenleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. *N Engl J Med*. 2000 May 4; 342(18):1309-1315.
12. American Academy of Pediatrics. Cytomegalovirus infection. In: Pickering LK, ed. *Red Book 2003 Report of the Committee on Infectious Diseases*. 26th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2003:259-262.
13. Skapova D, Racil Z, Dvorakova D, Minarikova D, Mayer J. Significance of qualitative PCR detection method for preemptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation—single-centre experience. *Neoplasma*. 2005; 52(2):137-142.
14. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. *Clin Microbiol Rev*. 2003 Oct; 16(4):647-657.
15. Razonable RR, Emery VC; 11th Annual Meeting of the IHMF (International Herpes Management Forum). Management of CMV infection and disease in transplant patients. 27-29 February 2004. *Herpes*. 2004 Dec; 11(3):77-86.
16. Peres E, Savasan S, Klein J, Abidi M, Dansey R, Abella E. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. *J Clin Microbiol*. 2005 Jul; 43(7):3540-3543.
17. Baldanti F, Grossi P, Furione M, et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. *J Clin Microbiol*. 2000 Feb; 38(2):613-619.
18. Limaye AP, Huang M-L, Atienza EE, Ferrenberg JM, Corey L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. *J Clin Microbiol*. 1999 Apr; 37(4):1113-1116.
19. Dummer JS. Risk factors and approaches to infections in transplant patients. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases*. 6th ed. vol 2. Philadelphia, Pa: Elsevier Churchill Livingstone; 2004:3476-3486.
20. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. *Clin Infect Dis*. 2005 Apr 1; 40(7):932-940.
21. Reddy S, Manna P. Quantitative detection and differentiation of human herpesvirus 6 subtypes in bone marrow transplant patients by using a single real-time polymerase chain reaction assay. *Biol Blood Marrow Transplant*. 2005 Jul; 11(7):530-541.



www.LabCorp.com



ViroMed
Laboratories
A LabCorp Company

www.ViroMed.com